title: Drug repurposing in pediatrics and pediatric hematology oncology.
abstract: Drug 'repurposing', that is, using old drugs for new indications, has been proposed as a more efficient strategy for drug development than the current standard of beginning with novel agents. In this review, we explore the scope of drug repurposing in pediatric hematology oncology and in pediatrics in general. Drugs commonly used in children were identified using the Harriet Lane Handbook (HLH) and searched in PubMed for different uses. Additional drugs were identified by searching PubMed and Google.com for 'drug repurposing' or 'drug repositioning'. Almost 10% of drugs with primary uses in pediatrics have been repurposed in pediatric hematology oncology or pediatrics. The observant clinician, pharmacologist and translational bioinformatician, as well as structural targeting, will have a role in discovering new repurposing opportunities.
authors: Department of Pediatrics and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. jblat@med.unc.edu
authors: Julie
authors: J
authors: Blatt
authors: Seth J
authors: SJ
authors: Corey
mesh_terms: D002648:Child; D019295:Computational Biology / Q000458:organization & administration; D017277:Drug Approval; D015195:Drug Design; D058492:Drug Repositioning; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D010372:Pediatrics; D057170:Translational Research, Biomedical / Q000458:organization & administration